MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcard.2023.131701

Медицинская библиотека · International journal of cardiology · 2023

Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis.

Moscarella Elisabetta, Ielasi Alfonso, Montonati Carolina, Pellegrini Dario, Pellicano Mariano, Briguglia Daniele, D'Alessandro Valentina, Giannini Francesco, Gamardella Marco, Medda Massimo, Guagliumi Giulio, Banfi Carlo, Glauber Mattia, Tespili Maurizio

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The new balloon-expandable (BE) Myval transcatheter heart valves (THV) has shown promising early results with low paravalvular leak (PVL) and permanent pacemaker implantation (PPI) rates. Limited data are available regarding its long-term performance. We aimed to compare the 2-year clinical and echocardiographic outcomes of transcatheter aortic valve replacement (TAVR) using the self-expanding (SE) Evolut R and the BE Myval THVs.

METHODS

The EVAL study included 166 patients with severe aortic valve stenosis who underwent TAVR either with SE Evolut R (n = 108) or BE Myval (n = 58) THV. Primary objectives include comparison on clinical efficacy (freedom from all-cause mortality, stroke, and cardiovascular hospitalization), echocardiographic performance and PPI rates between the two THVs.

RESULTS

At 2-year the BE Myval group showed higher clinical efficacy (86% vs. 66%,HR:2.62, 95%CI 2.2-5.1;p = 0.006), with fewer cardiac hospitalizations (3.4% vs. 13.9%,p = 0.03). No significant differences in all-cause mortality, cardiovascular mortality, or stroke rates were observed. The proportion of patients with ≥moderate PVL was significantly lower in the BE Myval compared to the SE Evolut R group (4%vs. 22%,p = 0.008). The mean transvalvular gradient was significantly higher in the SE group compared to the BE group (9.5 ± 4.3 vs. 6.9 ± 2.2 mmHg,p < 0.001), however there was no difference in the percentage of patients with a mean gradient ≥20 mmHg between the two groups.

CONCLUSIONS

Both THVs offer similar 2-year clinical outcomes. The BE Myval THV demonstrated advantages with higher clinical efficacy and lower PVL incidence. Longer follow-up and randomized trials are needed to validate these results and assess Myval's sustained performance and durability.

Для цитирования: Moscarella Elisabetta, Ielasi Alfonso, Montonati Carolina, Pellegrini Dario, Pellicano Mariano, Briguglia Daniele, D'Alessandro Valentina, Giannini Francesco, Gamardella Marco, Medda Massimo, Guagliumi Giulio, Banfi Carlo, Glauber Mattia, Tespili Maurizio. Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis.. International journal of cardiology. 2023. DOI: 10.1016/j.ijcard.2023.131701.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.